Peptide-based immunotherapy in lupus: Where are we now?

Rheumatol Immunol Res. 2023 Sep 27;4(3):139-149. doi: 10.2478/rir-2023-0020. eCollection 2023 Sep.

Abstract

In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further exacerbates inflammation that ultimately causes tissue and organ damage. Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology. This review summarizes the state-of-the-art therapeutic use of peptide-based therapies in autoimmune rheumatic diseases, with a specific focus on lupus.

Keywords: chemokine; cytokine; immune tolerance; immunotherapy; lupus; peptide; regulatory T cells.

Publication types

  • Review